Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models

In summary, our data demonstrated that CS-866 was effective in early and late stage retinopathy models through the inhibition of the angiotensin AT1 receptor. These findings suggest the possibility of CS-866 as a therapeutic agent for diabetic retinopathy.